CNS Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about CNS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 77 trials

Recruiting
Not Applicable

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

Brain CancerGliomasRecurrent CNS Tumors+3 more
National Cancer Institute (NCI)80 enrolled1 locationNCT07374692
Recruiting
Not Applicable

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

MelanomaBreast Cancer, NOSCNS Primary Tumor, NOS+9 more
Eastern Cooperative Oncology Group400 enrolled347 locationsNCT05108298
Recruiting
Not Applicable

Effect of a Driving Pressure Adjustment Procedure for High-Frequency Jet Ventilation in Patients Undergoing Tumor Thermal Ablation in Interventional Radiology

Solid Tumor (Excluding CNS)
Nantes University Hospital560 enrolled7 locationsNCT07408375
Recruiting

International Rare Brain Tumor Registry

AstroblastomaBCOR ITD SarcomaCNS Sarcoma+1 more
Children's National Research Institute5,800 enrolled10 locationsNCT05697874
Recruiting

Characterizing Sleep Among Long-term Survivors of Childhood Cancer

Solid TumorALL, AdultCNS Tumor
St. Jude Children's Research Hospital120 enrolled1 locationNCT05480904
Recruiting

Avera Cancer Sequencing and Analytics Protocol (ASAP)

Breast CancerOvarian CancerEndometrial Cancer+9 more
Avera McKennan Hospital & University Health Center25,000 enrolled6 locationsNCT05142033
Recruiting
Phase 2

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

CNS TumorHigh Grade Glioma
St. Jude Children's Research Hospital52 enrolled2 locationsNCT06528691
Recruiting
Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled6 locationsNCT04732065
Recruiting
Phase 2

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

Primary CNS Lymphoma (PCNSL)
The Lymphoma Academic Research Organisation60 enrolled13 locationsNCT06931652
Recruiting
Phase 1

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Secondary Central Nervous System LymphomaPrimary Central Nervous System (CNS) Lymphoma
Memorial Sloan Kettering Cancer Center12 enrolled7 locationsNCT07137494
Recruiting
Phase 2

A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)

Primary Central Nervous System LymphomaPCNSL
Tongji Hospital110 enrolled3 locationsNCT07350850
Recruiting
Phase 1

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

PineoblastomaEmbryonal Tumor With Multilayered RosettesEpendymoma+3 more
Children's National Research Institute12 enrolled1 locationNCT06193759
Recruiting
Phase 1Phase 2

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

ALK Fusion-positive Solid or CNS Tumors
Hoffmann-La Roche42 enrolled33 locationsNCT04774718
Recruiting
Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

CNS Embryonal TumorCNS, Medulloblastoma
C17 Council15 enrolled12 locationsNCT06942039
Recruiting
Phase 1

A Study of Avutometinib for People With Solid Tumor Cancers

Solid TumorSolid Tumor, AdultNeuroblastoma+12 more
Memorial Sloan Kettering Cancer Center23 enrolled2 locationsNCT06104488
Recruiting

Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors

Artificial Intelligence (AI)Digital HealthGlioma+1 more
Tata Memorial Centre600 enrolled1 locationNCT07236840
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 2

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Medulloblastoma RecurrentEpendymoma RecurrentATRT Recurrent+1 more
Medical University of Vienna232 enrolled22 locationsNCT01356290
Recruiting
Phase 1

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System Lymphoma+4 more
Memorial Sloan Kettering Cancer Center26 enrolled8 locationsNCT07082868
Recruiting
Phase 1

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Hepatocellular CarcinomaRhabdomyosarcomaWilms Tumor+7 more
Seattle Children's Hospital21 enrolled1 locationNCT07148050